This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Pain	CD93 (C1QR); VGF nerve growth factor inducible (VGF)	<i>In vitro</i> and rat studies suggest inhibiting C1QR could help treat neuropathic pain. VGF and the VGF-derived neuropeptide TLQP-21 increase sensitivity to pain. <i>In vitro</i> analysis identified C1QR as a receptor for TLQP-21. In a rat model of neuropathic pain, a mAb targeting the globular heads of C1QR delayed the onset of mechanical hypersensitivity compared with control IgG. Next steps include studies to extend the duration of efficacy of the C1QR-targeted mAb.	Patented; licensing status available from Imperial Innovations Group plc, the technology transfer arm of Imperial College London	Chen, Y.-C. <i>et al. J. Biol. Chem.</i> ; published online Oct. 8, 2013; doi:10.1074/jbc.M113.510917 Contact: Kenji Okuse, Imperial College London, London, U.K. e-mail: k.okuse@imperial.ac.uk
<i>SciBX</i> 6(44); doi:10.1038/scibx.2013.1270 Published online Nov. 14, 2013				